Essential Programme on Immunization
The Essential Programme on Immunization aims to strengthen vaccine programmes, supply, and delivery, and ensure universal access to all relevant vaccines for all populations across the life course.

 

Building on the momentum of the smallpox eradication effort, the Expanded Programme on Immunization (EPI) was launched in 1974 to ensure that all children, in all countries, benefited from life-saving vaccines. This programme has evolved into what is now commonly known as the Essential Programme on Immunization.

Today every country in the world has a national immunization programme and vaccines are viewed as one of the safest, most cost-effective, and successful public health interventions to prevent deaths and improve lives. Since the initial focus on protection against six childhood vaccine-preventable diseases (Bacillus Calmette-Guérin (BCG), diphtheria, pertussis, tetanus, polio, and measles) over four decades ago, the addition of new vaccines has increased the breadth of protection provided by immunization, to include vaccinations for protection of older children, adolescents and adults.

There are now 13 vaccines (antigens) recommended by WHO for the EPI programme. They are: Bacillus Calmette-Guérin (BCG), diphtheria, pertussis, tetanus, Haemophilus influenzae type B (Hib), Hepatitis B (HepB), polio, measles, rubella, pneumococcal disease (PNC), rotavirus (Rota), human papillomavirus (HPV), and COVID-19 (for adults).

Committed to its goal of universal access to all relevant vaccines for all at risk, EPI continues to work in synergy with other public health programmes to control infectious diseases and achieve better health for all populations everywhere. 

In 2024, it will be 50 years since the Expanded Programme on Immunization (EPI) was initiated.

 

infant-immunization

Publications

All →
Performance of Certest Biotec’s VIASURE yellow fever real time PCR detection kit: assessment report and recommendations for use in surveillance
On a need’s basis, the Immunization Analysis and Insights, Vaccine Preventable Diseases (VPD) Surveillance and Risk Assessment Team of the World Health...
Research and development technology roadmap for invasive non-typhoidal Salmonella vaccines against invasive disease

Invasive non-typhoidal serovars of Salmonella enterica, S. Typhimurium and S. Enteritidis, (iNTS) were estimated to cause over 500 000 invasive disease...

WHO preferred product characteristics for invasive non-typhoidal Salmonella vaccines

Invasive non-typhoidal serovars of Salmonella enterica, S. Typhimurium and S. Enteritidis, (iNTS) were estimated to cause over 500 000 invasive disease...

News

All →